Cargando…

A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa

INTRODUCTION: Although a considerable body of knowledge has been accumulated regarding the early diagnosis and treatment of oral squamous cell carcinoma (OSCC), its survival rates have not improved over the last decades. Thus, deciphering the molecular mechanisms governing oral cancer will support t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehterov, Nikolay, Sacconi, Andrea, Pulito, Claudio, Vladimirov, Boyan, Haralanov, Georgi, Pazardjikliev, Dimitar, Nonchev, Boyan, Berindan-Neagoe, Ioana, Blandino, Giovanni, Sarafian, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753689/
https://www.ncbi.nlm.nih.gov/pubmed/36531016
http://dx.doi.org/10.3389/fonc.2022.1072579
_version_ 1784851019438489600
author Mehterov, Nikolay
Sacconi, Andrea
Pulito, Claudio
Vladimirov, Boyan
Haralanov, Georgi
Pazardjikliev, Dimitar
Nonchev, Boyan
Berindan-Neagoe, Ioana
Blandino, Giovanni
Sarafian, Victoria
author_facet Mehterov, Nikolay
Sacconi, Andrea
Pulito, Claudio
Vladimirov, Boyan
Haralanov, Georgi
Pazardjikliev, Dimitar
Nonchev, Boyan
Berindan-Neagoe, Ioana
Blandino, Giovanni
Sarafian, Victoria
author_sort Mehterov, Nikolay
collection PubMed
description INTRODUCTION: Although a considerable body of knowledge has been accumulated regarding the early diagnosis and treatment of oral squamous cell carcinoma (OSCC), its survival rates have not improved over the last decades. Thus, deciphering the molecular mechanisms governing oral cancer will support the development of even better diagnostic and therapeutic strategies. Previous studies have linked aberrantly expressed microRNAs (miRNAs) with the development of OSCC. METHODS: We combined bioinformatical and molecular methods to identify miRNAs with possible clinical significance as biomarkers in OSCC. A set of 10 miRNAs were selected via an in silico approach by analysing the 3’untranslated regions (3’UTRs) of cancer-related mRNAs such as FLRT2, NTRK3, and SLC8A1, TFCP2L1 and etc. RT-qPCR was used to compare the expression of in silico identified miRNAs in OSCC and normal tissues (n=32). RESULTS: Among the screened miRNAs, miR-21-5p (p < 0.0001), miR-93-5p (p < 0.0197), miR-146b-5p (p <0.0012), miR-155-5p (p < 0.0001), miR-182-5p (p < 0.0001) were significantly overexpressed, whereas miR-133b (p < 0.05) was significantly downregulated in OSCC tissues, a scenario confirmed in two additional OSCC validation cohorts: Regina Elena National Cancer Institute (IRE cohort, N=74) and The Cancer Genome Atlas Data Portal (TCGA cohort, N=354). Initial stage tumors (T1, T2) expressed significantly higher levels of miR-133b (p < 0.0004) compared to more advanced ones (T3, T4). Also, we identified miR-93-5p (p < 0.0003), miR-133b (p < 0.0017) and miR-155-5p (p < 0.0004) as correlated with HPV-induced OSCC. The high expression of these 6 miRNAs as a signature predicted shorter disease-free survival (DFS) and could efficiently distinguish OSCC cases from healthy controls with areas under the curve (AUC) of 0.91 with sensitivity and specificity of 0.98 and 0.6, respectively. Further target identification analysis revealed enrichment of genes involved in FOXO, longevity, glycan biosynthesis and p53 cancer-related signaling pathways. Also, the selected targets were underexpressed in OSCC tissues and showed clinical significance related to overall survival (OS) and DFS. DISCUSSION: Our results demonstrate that a novel panel consisting of miR-21-5p, miR-93-5p, miR-133b, miR-146b-5p, miR-155-5p and miR-182-5p could be used as OSCC-specific molecular signature with diagnostic and prognostic significance related to OS and DFS.
format Online
Article
Text
id pubmed-9753689
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97536892022-12-16 A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa Mehterov, Nikolay Sacconi, Andrea Pulito, Claudio Vladimirov, Boyan Haralanov, Georgi Pazardjikliev, Dimitar Nonchev, Boyan Berindan-Neagoe, Ioana Blandino, Giovanni Sarafian, Victoria Front Oncol Oncology INTRODUCTION: Although a considerable body of knowledge has been accumulated regarding the early diagnosis and treatment of oral squamous cell carcinoma (OSCC), its survival rates have not improved over the last decades. Thus, deciphering the molecular mechanisms governing oral cancer will support the development of even better diagnostic and therapeutic strategies. Previous studies have linked aberrantly expressed microRNAs (miRNAs) with the development of OSCC. METHODS: We combined bioinformatical and molecular methods to identify miRNAs with possible clinical significance as biomarkers in OSCC. A set of 10 miRNAs were selected via an in silico approach by analysing the 3’untranslated regions (3’UTRs) of cancer-related mRNAs such as FLRT2, NTRK3, and SLC8A1, TFCP2L1 and etc. RT-qPCR was used to compare the expression of in silico identified miRNAs in OSCC and normal tissues (n=32). RESULTS: Among the screened miRNAs, miR-21-5p (p < 0.0001), miR-93-5p (p < 0.0197), miR-146b-5p (p <0.0012), miR-155-5p (p < 0.0001), miR-182-5p (p < 0.0001) were significantly overexpressed, whereas miR-133b (p < 0.05) was significantly downregulated in OSCC tissues, a scenario confirmed in two additional OSCC validation cohorts: Regina Elena National Cancer Institute (IRE cohort, N=74) and The Cancer Genome Atlas Data Portal (TCGA cohort, N=354). Initial stage tumors (T1, T2) expressed significantly higher levels of miR-133b (p < 0.0004) compared to more advanced ones (T3, T4). Also, we identified miR-93-5p (p < 0.0003), miR-133b (p < 0.0017) and miR-155-5p (p < 0.0004) as correlated with HPV-induced OSCC. The high expression of these 6 miRNAs as a signature predicted shorter disease-free survival (DFS) and could efficiently distinguish OSCC cases from healthy controls with areas under the curve (AUC) of 0.91 with sensitivity and specificity of 0.98 and 0.6, respectively. Further target identification analysis revealed enrichment of genes involved in FOXO, longevity, glycan biosynthesis and p53 cancer-related signaling pathways. Also, the selected targets were underexpressed in OSCC tissues and showed clinical significance related to overall survival (OS) and DFS. DISCUSSION: Our results demonstrate that a novel panel consisting of miR-21-5p, miR-93-5p, miR-133b, miR-146b-5p, miR-155-5p and miR-182-5p could be used as OSCC-specific molecular signature with diagnostic and prognostic significance related to OS and DFS. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9753689/ /pubmed/36531016 http://dx.doi.org/10.3389/fonc.2022.1072579 Text en Copyright © 2022 Mehterov, Sacconi, Pulito, Vladimirov, Haralanov, Pazardjikliev, Nonchev, Berindan-Neagoe, Blandino and Sarafian https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mehterov, Nikolay
Sacconi, Andrea
Pulito, Claudio
Vladimirov, Boyan
Haralanov, Georgi
Pazardjikliev, Dimitar
Nonchev, Boyan
Berindan-Neagoe, Ioana
Blandino, Giovanni
Sarafian, Victoria
A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title_full A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title_fullStr A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title_full_unstemmed A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title_short A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa
title_sort novel panel of clinically relevant mirnas signature accurately differentiates oral cancer from normal mucosa
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753689/
https://www.ncbi.nlm.nih.gov/pubmed/36531016
http://dx.doi.org/10.3389/fonc.2022.1072579
work_keys_str_mv AT mehterovnikolay anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT sacconiandrea anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT pulitoclaudio anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT vladimirovboyan anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT haralanovgeorgi anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT pazardjiklievdimitar anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT nonchevboyan anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT berindanneagoeioana anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT blandinogiovanni anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT sarafianvictoria anovelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT mehterovnikolay novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT sacconiandrea novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT pulitoclaudio novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT vladimirovboyan novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT haralanovgeorgi novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT pazardjiklievdimitar novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT nonchevboyan novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT berindanneagoeioana novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT blandinogiovanni novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa
AT sarafianvictoria novelpanelofclinicallyrelevantmirnassignatureaccuratelydifferentiatesoralcancerfromnormalmucosa